Trial Profile
A Phase 1b, Randomized, Uncontrolled, Single-masked, Safety, Tolerability, and Pharmacokinetic Study of Multiple Doses of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Human Subjects Undergoing Elective Pars Plana Vitrectomy (PPV)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Lifitegrast (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- 09 May 2017 Status changed from recruiting to discontinued.
- 19 Jun 2014 New trial record